Loading...
Immune checkpoint inhibitors in mCRPC - rationales, challenges and perspectives
The advancement of immune-therapeutics in cancer treatment has proven to be promising in various malignant diseases. However, in castration resistant prostate cancer (mCRPC) major Phase III trials have been unexpectedly disappointing. To contribute to a broader understanding of the role and use of i...
Na minha lista:
| Udgivet i: | Oncoimmunology |
|---|---|
| Main Authors: | , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Taylor & Francis
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6791446/ https://ncbi.nlm.nih.gov/pubmed/31646092 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2019.1644109 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|